BCG treatment after bladder tumor removal for early bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at whether the bladder is ready to receive BCG, a medicine placed directly into the bladder, after surgeons remove a new bladder lesion. It may help doctors understand the best timing and preparation for BCG in early (non-muscle-invasive) bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are having a complete TURBT procedure to check a newly found bladder lesion
- After TURBT, you are diagnosed with NMIBC (bladder cancer that has not grown into the bladder muscle)
- Your pathology results show low-risk or high-risk NMIBC, not muscle-invasive cancer
- You must give informed consent to join the study
- You must not have a visible tumor seen during the first or any follow-up cystoscopy
- You must not have a urinary tract infection before the cystoscopy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This study tests if BCG therapy can prevent bladder cancer from coming back after surgery. It's for people with early-stage bladder cancer that hasn't spread into the muscle layer.
This trial tests if a special type of tumor removal (ERBT) followed by BCG immunotherapy is better than standard treatment for medium- or high-risk non-muscle-invasive bladder cancer. It may help people whose bladder cancer has come back, has multiple tumors, or has a tumor larger than 1 cm.
This study tries to predict whether BCG treatment will work for people with certain early-stage bladder cancers. It may help doctors better choose and monitor BCG for similar patients in the future.
This study is testing whether a urine or blood test can help guide BCG treatment for high-risk bladder cancer that hasn't spread into the muscle. It is only for people over 65 who are new to BCG therapy.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
Hear when a new Non-Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.